Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascentage Pharma Group International ( (HK:6855) ) has provided an update.
Ascentage Pharma Group International reported a significant decrease in revenue for the first half of 2025, primarily due to a drop in intellectual property revenue compared to the previous year. Despite this, product sales of Olverembatinib in China saw a substantial increase, attributed to its inclusion in the National Reimbursement Drug List, enhancing its affordability and accessibility. The company also marked a milestone with the approval of Lisaftoclax in China for treating chronic lymphocytic leukemia/small lymphocytic lymphoma, highlighting its strategic execution in clinical development. This approval positions Ascentage Pharma as a key player in the Bcl-2 inhibitor market, with implications for increased market presence and stakeholder interest.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel, differentiated therapies to address unmet medical needs in cancer. Their lead drug products, Olverembatinib and Lisaftoclax, target major hematological malignancies and solid tumors, with a significant market focus on diseases like chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, and others.
Average Trading Volume: 5,675,960
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.46B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.